First Trust NASDAQ Clean Edge Green Energy Idx Fd vs Repligen Corporation Common Stock — how do they compare? First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $44.72 (market cap $524.91M), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 21.2× First Trust NASDAQ Clean Edge Green Energy Idx Fd's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, First Trust NASDAQ Clean Edge Green Energy Idx Fd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold First Trust NASDAQ Clean Edge Green Energy Idx Fd for 52 Days and Repligen Corporation Common Stock for 0 Days on average.
| QCLN | RGEN | |
|---|---|---|
Market Cap | $524.91M | $11.14B |
Volume | 261,814 | 1,259,263 |
Sector | Sector/Thematic | Health |
52-Week High | $68.47 | $194.57 |
52-Week Low | $41.10 | $102.87 |
Typical Hold Time | 52 Days | 0 Days |
Enterprise Value | — | $11.02B |
Signals from Pluang's Aura AI — not financial advice
QCLN trades at $47.24, showing minimal daily movement with a 0.25% gain. Technical indicators signal bearish momentum as the stock trades below key moving averages, though oversold RSI conditions suggest potential near-term support. Recent news highlights the ETF's sensitivity to political outcomes and global energy transitions, with geopolitical tensions driving renewed interest in clean energy investments.
The fund's performance remains heavily dependent on policy developments and energy market dynamics. While global renewable energy acceleration provides long-term tailwinds, near-term volatility persists due to political uncertainty and technical weakness. Investors face balanced risk-reward with policy catalysts potentially offsetting current bearish technical signals.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →